How Do CD4+ T Cells Detect and Eliminate Tumor Cells That Either Lack or Express MHC Class II Molecules?
Open Access
- 15 April 2014
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 5, 174
- https://doi.org/10.3389/fimmu.2014.00174
Abstract
CD4+ T cells contribute to tumor eradication, even in the absence of CD8+ T cells. Cytotoxic CD4+ T cells can directly kill MHC class II positive tumor cells. More surprisingly, CD4+ T cells can indirectly eliminate tumor cells that lack MHC class II expression. Here, we review the mechanisms of direct and indirect CD4+ T cell-mediated elimination of tumor cells. An emphasis is put on T cell receptor (TCR) transgenic models, where anti-tumor responses of naïve CD4+ T cells of defined specificity can be tracked. Some generalizations can tentatively be made. For both MHCIIPOS and MHCIINEG tumors, presentation of tumor specific antigen by host antigen presenting cells (APCs) appears to be required for CD4+ T cell priming. This has been extensively studied in a myeloma model (MOPC315), where host APCs in tumor-draining lymph nodes are primed with secreted tumor antigen. Upon antigen recognition, naïve CD4+ T cells differentiate into Th1 cells and migrate to the tumor. At the tumor site, the mechanisms for elimination of MHCIIPOS and MHCIINEG tumor cells differ. In a TCR transgenic B16 melanoma model, MHCIIPOS melanoma cells are directly killed by cytotoxic CD4+ T cells in a perforin/granzyme B-dependent manner. By contrast, MHCIINEG myeloma cells are killed by IFN-g stimulated M1-like macrophages. In summary, while the priming phase of CD4+ T cells appears similar for MHCIIPOS and MHCIINEG tumors, the killing mechanisms are different. Unresolved issues and directions for future research are addressed.Keywords
This publication has 105 references indexed in Scilit:
- Depleting tumor-specific Tregs at a single site eradicates disseminated tumorsJCI Insight, 2013
- Inflammation driven by tumour-specific Th1 cells protects against B-cell cancerNature Communications, 2011
- Effector T cell plasticity: flexibility in the face of changing circumstancesNature Immunology, 2010
- Mechanisms Underlying Lineage Commitment and Plasticity of Helper CD4 + T CellsScience, 2010
- Naive tumor-specific CD4+ T cells differentiated in vivo eradicate established melanomaThe Journal of Experimental Medicine, 2010
- Tumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hostsThe Journal of Experimental Medicine, 2010
- Tumor-specific Th17-polarized cells eradicate large established melanomaBlood, 2008
- Treatment of Metastatic Melanoma with Autologous CD4+ T Cells against NY-ESO-1New England Journal of Medicine, 2008
- Lymphomas can develop from B cells chronically helped by idiotype-specific T cellsThe Journal of Experimental Medicine, 2007
- MHC class II transactivator (CIITA) expression is upregulated in multiple myeloma cells by IFN-γMolecular Immunology, 2007